expressed continued concerns about the epidemic of prescription drug abuse and pushed for timely and effective legislative solutions
Support legislative solutions to curb prescription drug abuse.
Occurrences
attack the problem through investigations, treatment and education.
I will remain vigilant in Washington to maintain federal support for these programs
Evidence
Rogers said he voted to reauthorize the SUPPORT Act and described it as legislation that includes enhanced Prescription Drug Monitoring Programs (PDMPs), increased treatment options for substance use disorder, support for treatment and recovery centers, law enforcement resources and improved access to naloxone. The post says the bill passed the House and moved to the Senate.
Rogers states that prescription drug abuse policy has been a life-saving priority for more than two decades. He says he long advocated for Prescription Drug Monitoring Programs, helped establish a national grant program to help states track and combat prescription drug abuse, and supported CARA, the 21st Century Cures Act, and the SUPPORT for Patients and Communities Act.
The Bureau of Justice Assistance posted the FY25 Harold Rogers Prescription Drug Monitoring Program solicitation, showing the program remained active in fiscal year 2025 with a closed status, a closing date of November 3, 2025, and a posting date of September 16, 2025.
BJA’s program page shows FY25 Harold Rogers PDMP activity, including a January 2025 performance-measures training, an October 1, 2025 webinar, and the FY25 solicitation deadlines.
DOJ announced more than $8.8 million in awards under the Harold Rogers Prescription Drug Monitoring Program FY 2016 competitive grant program, explaining that PDMPs help improve pain management care, prevent diversion, and identify patients who may need treatment.
Assessments
Rogers materially supported and advanced federal legislative and appropriations solutions to prescription drug abuse while serving in Congress, including long-running support for prescription drug monitoring programs, federal grant funding, and votes for major opioid-related laws such as CARA, the 21st Century Cures Act, and SUPPORT Act measures. Because the promise was to support legislative solutions rather than single-handedly enact a specific bill, the documented voting, sponsorship/appropriations role, and active federal program implementation satisfy the claim in the same federal office context.
The promise was broadly framed as supporting legislative solutions to curb prescription drug abuse, and the evidence shows Rogers did that through sustained advocacy, votes, and support for enacted federal measures. The record cites his backing for Prescription Drug Monitoring Programs, help establishing a national grant program, and support for major opioid and prescription-drug legislation such as CARA, the 21st Century Cures Act, and the SUPPORT Act. The DOJ grant awards and the continuing Harold Rogers PDMP program show these efforts translated into implemented federal policy, not just rhetoric. Because the promise is about support for legislative solutions rather than personally enacting a specific bill, this level of documented support and resulting policy infrastructure is sufficient for delivery. Key implementation and legislative support occurred while he was in office, so same_term is the best fit, even though the program continued later as well.